ESTRO 2023 - Abstract Book

S1953

Digital Posters

ESTRO 2023

between the isodose lines. The preliminary results on the first 150 (10%) patients without prostate calcifications for the dosimetric comparison between the MC simulations and the TG43 calculations are shown in table 1. The mean differences found in the dosimetric indices are consistent with published results given the neglected interseed attenuation and the point source approximation used in clinical dose calculations.

Conclusion In this work, a validated systematic MC dose recalculation pipeline for permanent implant brachytherapy is built and launched on a large-scale patient cohort. Based on the produced patient specific dose distributions, the weaknesses of the TG43 calculation are characterized for real patient treatments. This dose dataset could be used in future work to study the dose-tissue response relationships.

PO-2170 Dosimetric comparison of AcurosTM BV and AAPM TG43 for interstitial HDR brachytherapy

Y. Roussakis 1 , G. Antorkas 1 , L. Gerogiou 1 , I. Strouthos 2 , E. Karagiannis 2 , K. Ferentinos 2 , N. Zamboglou 2 , P. Doolan 1 , G. Anagnostopoulos 1 1 German Oncology Center, Department of Medical Physics, Limassol, Cyprus; 2 German Oncology Center, Department of Radiation Oncology, Limassol, Cyprus

Purpose or Objective